My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Articles published by Cure Rare Disease

Cure Rare Disease Awarded $7.4 Million CIRM Grant to Advance Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9

December 15, 2025

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Secures FDA Orphan Drug Designation for Investigational Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type R9 (LGMD2i/R9)

September 24, 2025

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting

June 24, 2025

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Welcomes New Scientific and Strategic Leaders to Advance Therapies for Ultra-Rare Conditions

June 09, 2025

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Receives Orphan Drug Designation from FDA for Investigational Therapy Targeting Spinocerebellar Ataxia Type 3 (SCA3)

May 14, 2025

From Cure Rare Disease

Via Business Wire

We Row For William: 157 Miles, One Nonstop Journey of Hope

April 03, 2025

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Awarded $5.69 Million CIRM Grant to Advance Gene Therapy for Spinocerebellar Ataxia Type 3

February 06, 2025

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer

December 18, 2024

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Expands Leadership Team and Board of Directors to Advance Mission

June 17, 2024

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Welcomes Leading Experts to Scientific Advisory Board

March 20, 2023

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Receives Muscular Dystrophy Association Grant

February 16, 2023

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Acquires Laboratory Space for New Headquarters in Connecticut

September 29, 2022

From Cure Rare Disease

Via Business Wire

Cure Rare Disease Receives FDA Approval to Administer First-in-Human CRISPR Therapeutic

August 10, 2022

From Cure Rare Disease

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.